Neumora Therapeutics (NMRA) announced the appointment of Kaya Pai Panandiker as chief commercial officer and a member of Neumora’s executive team, reporting to Henry Gosebruch, president and chief executive officer. Pai Panandiker has more than 20 years of experience commercializing medicines in areas of significant unmet need, including the commercial launches of TRINTELLIX and REXULTI for major depressive disorder and schizophrenia. Prior to joining Neumora, Pai Panandiker served as head of commercial at Cerevel Therapeutics (CERE) and general manager, neuroscience at Lundbeck US.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NMRA:
- Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer
- The biopharmaceuticals stocks to own in 2024, according to BofA
- Neumora Therapeutics price target raised to $20 from $18 at BofA
- Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
- Neumora Therapeutics appoints Jason Duncan as CLO
